Physician profile
Roger D Bies
NPI 1912973439
$4,769.84
in general payments reported to CMS, 2019-2025
30 companies · $427 in 2025
The $427 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $305 · 2021: $667 · 2022: $1,057 · 2023: $780 · 2024: $461 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,668.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,790.41 | 2019-2025 | Ffrct |
| Siemens Medical Solutions USA, INC. | $859.57 | 2019-2023 | Somatom Force, Biograph Vision 600 (8 Ring/64 Ct) |
| Boston Scientific Corporation | $312.48 | 2019-2024 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $262.14 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $206.61 | 2019-2022 | |
| Biotronik INC. | $196.65 | 2019 | |
| Bard Peripheral Vascular, INC. | $150.00 | 2019 | |
| Viz.Ai, INC. | $137.99 | 2022 | |
| Cleerly, INC. | $134.81 | 2023-2025 | Cleerly Ischemia, Cleerly Labs |
| Novartis Pharmaceuticals Corporation | $90.80 | 2019-2025 | |
| Pfizer INC. | $67.14 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.63 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $49.10 | 2022 | |
| Atricure, INC. | $48.75 | 2024 | |
| Merck Sharp & Dohme LLC | $45.45 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $38.77 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $37.48 | 2019-2022 | |
| Bardy Diagnostics, INC. | $35.00 | 2020 | |
| Philips North America LLC | $28.87 | 2023 | |
| Genentech USA, INC. | $24.93 | 2023 | |
| Janssen Pharmaceuticals, INC | $24.85 | 2021 | |
| Akcea Therapeutics, INC. | $24.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.67 | 2019-2020 | |
| Cvrx, INC. | $22.09 | 2024 | Barostim Neo System |
| Angiodynamics, INC. | $20.61 | 2021 | |
| Amgen INC. | $19.49 | 2023 | Repatha |
| Astellas Pharma US INC | $19.35 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.25 | 2023 | Inpefa |
| Alnylam Pharmaceuticals INC. | $14.09 | 2024 | Amvuttra |
| Tactile Systems Technology INC | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Bies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.